| Poisson regression | |
---|---|---|
 | Duration of Steroid Use | |
 | RR | CI |
Age ( 5Â year decrease) | 1.19 | (1.08, 1.31)e |
Female | 1.40 | (0.97, 2.02) |
Caucasian | 1.39 | (0.80, 2.42) |
Region | Â | Â |
 Midwest | 1.00 | Reference |
 Northeast | 0.86 | (0.56, 1.32) |
 Southeast | 0.71 | (0.46, 1.08) |
 Southwest | 0.60 | (0.30, 1.18) |
 Rocky Mountain | 0.42 | (0.09, 2.05) |
 Pacific & HI, AK, Prf | 0.60 | (0.29, 1.23) |
Rural | 1.23 | (0.86, 1.77) |
Medicaid eligible | 1.04 | (0.72, 1.51) |
antiTNFs | 0.62 | (0.19, 2.03) |
Nonbiologic immunomodulators | 1.58 | (0.75, 3.33) |
Aminosalicylates | 1.41 | (0.98, 2.03) |
Locally administered steroids | 4.39 | (1.51, 12.70)d |
Antidiarrheals | 1.07 | (0.69, 1.65) |
Charlson index | 0.96 | (0.90, 1.01) |
Hospitalizations | 0.96 | (0.87, 1.05) |
Endoscopy (>1) | 0.87 | (0.60, 1.27) |
IBD-associated Surgery | 0.68 | (0.35, 1.33) |